Lung Cancer Foundation of America logo
Donate
  • About Us
    • History
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest In Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • Survivor Stories
    • Tributes
    • Hope With Answers℠
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy
  • Hope
  • Research
  • Life
  • About Us
    • History
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest In Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • Survivor Stories
    • Tributes
    • Hope With Answers℠
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy
  • Donate
  • Hope
  • Research
  • Life

What Can We Help You Find?

WHAT ARE THE MOST COMMONLY TESTED MUTATIONS AND TREATMENTS?

Many genetic mutations have been identified in lung cancer tumors, and the mutations that have FDA-approved targeted therapies are increasing. All metastatic adenocarcinoma tumors should be tested for EGFR and ALK, as should some squamous tumors. Even though we only have a few FDA-approved targeted therapies, many more mutations have been identified and are being studied in ongoing clinical trials for use in these other mutations.

What Targeted Therapies Are Currently Available?

EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR)

a. EGFR MUTATION POSITIVE

The EGFR receptor targets in a lung cancer cell can make it sensitive to what are known as “EGFRinhibitors.” A patient’s tumor is referred to as “EGFR mutation positive” if it has this gene alteration in its cells. Examples of EGFR inhibitors are the drugs Tarceva® and Gilogrif®.

When a patient has an “EGFR mutation positive” tumor, his/her cancer can be highly sensitive to treatment with drugs like Tarceva® and Gilogrif®. Side effects of this treatment may include diarrhea and rash, although these side effects are usually manageable. In this situation, patients can actually receive Tarceva® and Gilogrif® before receiving any chemotherapy.

This treatment can cause the cancer to remain stable or even cause the cancer to disappear for a period of time.

NOTE: There are some uncommon mutant versions of EGFR that don’t respond to treatment with Tarceva® and Gilogrif® even though they are “EGFR mutation positive.” For these patients’ lung cancers (as for those patients whose tumor is resistant to Tarceva® or Gilogrif®) there are new “next generation” inhibitors being developed.

b. EGFR MUTATION NEGATIVE

When lung cancer tumor cells do NOT have the EGFR mutation, they are called “EGFR negative” or “EGFR wildtype.” These tumors are likely to be less sensitive to drugs like Tarceva®. The drug may still inhibit cancer growth, but is less likely to cause dramatic tumor shrinkage. In this case, the drug may be used after other treatments are used first, and it is called a “second-line” or “third-line” treatment option.

ALK (ANAPLASTIC LYMPHOMA KINASE)

ALK mutations are found in a smaller number of non-small cell lung cancer patients than the EGFR mutations. There are several ways to test for ALK mutations using tumor samples but the most frequent method is to use a test known by the acronym “FISH.”

“ALK Mutation Positive”

Tumors with this mutation are likely to be highly sensitive to new drugs like Xalkori® and ZyKadia®, which are “ALK inhibitors.” Most patients report only mild side effects. New next generation ALK inhibitors are available in clinical trials and may be even more effective. They may even work in tumors that have become resistant, meaning they initially responded to Xalkori® or ZyKadia®, but have stopped responding.

WHAT OTHER MUTATIONS OR MARKERS ARE BEING TESTED FOR OR INVESTIGATED?

 

There are other mutations currently being studied as candidates for therapeutic targets with early promising results.    Patients should consider getting tested for all gene mutations, as new targeted therapies are being developed. Patients may also wish to consider participating in clinical trials for which they are qualified, as all new drugs must go through this standard approval process.

 

  • HER2 –
  • MET –
  • RET
  • ROS1 –
  • IGF1R –
  • BRAF
  • PIK3CA –
  • ERBB2 –
  • PD-L1

 


LCFA Personalized Medicine Brochure 2017 Pie Chart


Donate Online

Your donation to Lung Cancer Foundation of America will help to fund research that will find new treatments for lung cancer patients everywhere.

Donation Amount

other amount

More

  • About Us
    • History
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest In Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • Survivor Stories
    • Tributes
    • Hope With Answers℠
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy

Our Mission

LCFA's mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease.

To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.



Latest In Research

12/4
2019

Treatment Refusal for Small Cell Lung Cancer

Treatment refusal for small cell lung cancer studied: Small-cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and the disease is not associated with a great outcome rate, with a 5-year survival of only around 6%. But S…

Sign up

Get the latest news about lung cancer research.

Connect with us



©2019 Lung Cancer Foundation of America. All Rights Reserved.

Sponsors    |    Legal    |    Media Contact    |    Videos    |   State Fundraising Notices